Virus tolerance in okra (Abelmoschus esculentus): Field screening strategies and sustainable management
Journal of Agriculture and Livestock Farming · 24.06.2026
DOI: 10.61577/jalf.2025.1000018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Agriculture and Livestock Farming, online erschienen am 24.06.2026. Verfasst von Nazim Uddin.
Abstract (Originalsprache)
Viral diseases, particularly Yellow Vein Mosaic Virus (YVMV) and Okra Leaf Curl Virus (OLCV), pose significant threats to okra (Abelmoschus esculentus L. Moench) production, leading to severe yield losses.This study focuses on the field screening of virus-tolerant okra genotypes to identify those with natural resistance under high virus pressure.A diverse set of genotypes was tested using aRandomized Complete Block Design (RCBD) in virus-prone areas.Disease incidence, severity index, and yield performance were evaluated.Genotypes exhibiting lower infection rates, reduced disease severity, and minimal yield loss were identified as virus-tolerant.The results indicate that these virus-tolerant genotypes can be recommended for cultivation in regions vulnerable to viral outbreaks, reducing dependency on chemical control methods and improving sustainable okra production.This approach offers a viable solution to enhance food security and ensure better economic outcomes for farmers.
Zitieren
APA
Uddin, N. (2026). Virus tolerance in okra (Abelmoschus esculentus): Field screening strategies and sustainable management. Journal of Agriculture and Livestock Farming. https://doi.org/10.61577/jalf.2025.1000018
Vancouver
Uddin N. Virus tolerance in okra (Abelmoschus esculentus): Field screening strategies and sustainable management. Journal of Agriculture and Livestock Farming. 2026. doi:10.61577/jalf.2025.1000018
BibTeX
@article{Uddin2026,
author = {Uddin, Nazim},
title = {Virus tolerance in okra (Abelmoschus esculentus): Field screening strategies and sustainable management},
journal = {Journal of Agriculture and Livestock Farming},
year = {2026},
doi = {10.61577/jalf.2025.1000018}
}
EUVIMED